Telix Pharmaceuticals Limited’s Price-to-Book Ratio at a glance
Telix Pharmaceuticals Limited reports price-to-book ratio of 14.3x for Dec 2024. The prior period recorded 21.6x (Dec 2023). Year over year the metric moved −7.26 (−33.6%). The rolling three-period average stands at 21.4x. Data last refreshed Dec 7, 2025, 2:50 AM.
Latest reading
14.3x · Dec 2024
YoY movement
−7.26 (−33.6%)
Rolling average
21.4x
Current Price-to-Book Ratio
14.3x
−7.26
−33.6%
Rolling average
21.4x
Latest Value
14.3x
Dec 2024
YoY Change
−7.26
Absolute
YoY Change %
−33.6%
Rate of change
3-Period Avg
21.4x
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s price-to-book ratio stands at 14.3x for Dec 2024. Year-over-year, the metric shifted by −7.26, translating into a −33.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-book ratio shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-book ratio of 14.3x. Monitor price-to-book trends to gauge how investors value tangible assets and equity on the balance sheet.
Capital-intensive industries
Banks, insurers, and industrials rely on P/B to judge returns on equity relative to book value.
Reading discount or premium
Ratios below 1.0 signal the market values equity below book, which could mean undervaluation or weak profitability.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s price-to-book ratio profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current price-to-book ratio?
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-book ratio of 14.3x. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's price-to-book ratio trending year over year?
Year-over-year, the figure shifts by −7.26 (−33.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does price-to-book ratio matter for Telix Pharmaceuticals Limited?
Price-to-book compares market value with book value of equity, highlighting balance sheet-driven valuation. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's price-to-book ratio above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 21.4x. Comparing the latest reading of 14.3x to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's price-to-book ratio refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:50 AM and updates automatically every 24 hours, keeping your valuation inputs current.